Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
SCYNEXIS Inc. has announced Phase 1 study results for Scy-770, an oral direct AMPK activator intended for the treatment of Autosomal Dominant Polycystic Kidney Disease.
SCYNEXIS announced Phase 1 study results for SCY-770, a novel, highly selective, oral direct AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The drug candidate was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated. A Phase 2 p